All In Biotech

Drug Trial Radar · NCT01928771

Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma

Last checked: Nov 20, 2026Latest source record: May 3, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,681 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,681

Actual

Start

Sep 19, 2013

Primary completion

Apr 5, 2016

Study completion Apr 5, 2016

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.

Conditions

  • Asthma

Interventions

  • BenralizumabBiological

    Benralizumab subcutaneously on study week 0 until study week 44 inclusive.

  • PlaceboBiological

    Placebo subcutaneously on study week 0 until study week 44 inclusive.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uLTime frame: Immediately following the first administration of study drug through Study Week 48.

Locations

275 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Foley, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Scottsboro, Alabama

  • Research Site

    Sheffield, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    Beverly Hills, California

  • Research Site

    Costa Mesa, California

  • Research Site

    Huntington Beach, California

  • Research Site

    Huntington Park, California

  • Research Site

    Los Angles, California

  • Research Site

    Newport Beach, California

  • Research Site

    Orange, California

  • Research Site

    Riverside, California

  • Research Site

    San Jose, California

  • Research Site

    Santa Ana, California

  • Research Site

    Hartford, Connecticut

  • Research Site

    New Haven, Connecticut

  • Research Site

    Brandon, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Cutler Bay, Florida

  • Research Site

    DeLand, Florida

  • Research Site

    Gainesville, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Homestead, Florida

  • Research Site

    Jackonsville, Florida

  • Research Site

    Lynn Haven, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Port Charlotte, Florida

  • Research Site

    Sebring, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Vero Beach, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Albany, Georgia

Showing 40 of 275 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.